Drug Profile
Influenza A virus H5N1 vaccine - Medicago
Alternative Names: H5N1 avian influenza virus-like particle (VLP) vaccine - Medicago; H5N1 VLP vaccine - Medicago; MT-8972; One-dose H5N1 VLP vaccine - Medicago; Pandemic flu vaccine - Medicago; Plant-derived influenza vaccines - Medicago; Plant-made H5 VLP influenza vaccine - MedicagoLatest Information Update: 17 Feb 2023
Price :
$50
*
At a glance
- Originator Medicago
- Developer Infectious Disease Research Institute; Medicago
- Class Influenza A virus H5N1 vaccines; Viral vaccines; Virus-like particle vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Discontinued Influenza A virus H5N1 subtype
Most Recent Events
- 17 Feb 2023 Discontinued - Phase-I for Influenza A virus H5N1 subtype (Prevention, In volunteers) in USA (IM) (Mitsubishi Tanabe Pharma pipeline, February 2023)
- 17 Feb 2023 Discontinued - Phase-I for Influenza A virus H5N1 subtype (Prevention, In volunteers) in USA (Intradermal) (Mitsubishi Tanabe Pharma pipeline, February 2023)
- 17 Feb 2023 Discontinued - Phase-II for Influenza A virus H5N1 subtype (Prevention, In volunteers) in Canada (IM) (Mitsubishi Tanabe Pharma pipeline, February 2023)